

Rivfloza® (nedosiran) - Expanded indication

- On March 27, 2025, the <u>FDA approved</u> Novo Nordisk's <u>Rivfloza (nedosiran)</u> to <u>lower urinary</u> oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., estimated glomerular filtration rate (eGFR) ≥ 30 mL/min/1.73 m².
 - Rivfloza was previously approved for this indication in children 9 years of age and older and adults.
- The approval of Rivfloza for the expanded indication was based on a single-arm study in 15 patients 2 years to less than 12 years of age with PH1 and eGFR ≥ 30 mL/min/1.73 m². Efficacy was based on the percent change from baseline at month 6 in spot urinary oxalate to creatinine ratio.
 - Treatment with Rivfloza reduced the spot urinary oxalate to creatinine ratio by 64% (95% CI: 44, 84) from baseline, with an absolute risk reduction of 0.25 mmol/mmol (95% CI: 0.21, 0.29).
- The recommended **once monthly subcutaneous** dose of Rivfloza for the expanded age group (children 2 to 9 years of age) is dependent on body weight:

Less than 39 kg: 3.3 mg/kg
39 kg to less than 50 kg: 128 mg
50 kg and above: 160 mg.

Refer to the Rivfloza drug label for dosing for previously indicated age groups.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews® is published by the Optum Rx Clinical Services Department.